Galmed Pharmaceuticals
Update in progressGLMD (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Galmed Pharmaceuticals Ltd. is a biopharma company developing liver-disease therapies. It advances Aramchol, a first-in-class synthetic fatty acid–bile acid conjugate in Phase III for oral treatment of overweight or obese patients with prediabetes or type 2 diabetes who have nonalcoholic steatohepatitis (NASH). It also studies Aramchol in the ARRIVE Phase IIa trial for HIV-associated NASH with lipodystrophy. Other programs include Amilo-5MER, a five-amino-acid peptide, and MyBiotics in preclinical NASH and fibrosis. Galmed licenses Aramchol rights in Korea to Samil Pharma and collaborates with OnKai on an AI platform. Founded 2000, headquartered in Ramat Gan, Israel.
Company score
- Sentiment
- 0.19
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.10
- Governance
- 0.16
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.12
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
No news articles are available for this company yet.
Unable to load company news.
You're all caught up!